EP1514106A4 - Proteines therapeutiques ciblees - Google Patents
Proteines therapeutiques cibleesInfo
- Publication number
- EP1514106A4 EP1514106A4 EP03736779A EP03736779A EP1514106A4 EP 1514106 A4 EP1514106 A4 EP 1514106A4 EP 03736779 A EP03736779 A EP 03736779A EP 03736779 A EP03736779 A EP 03736779A EP 1514106 A4 EP1514106 A4 EP 1514106A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- therapeutic proteins
- targeted therapeutic
- targeted
- proteins
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US272531 | 1994-07-11 | ||
| US38445202P | 2002-05-29 | 2002-05-29 | |
| US384452P | 2002-05-29 | ||
| US38601902P | 2002-06-05 | 2002-06-05 | |
| US386019P | 2002-06-05 | ||
| US40881602P | 2002-09-06 | 2002-09-06 | |
| US408816P | 2002-09-06 | ||
| US10/272,531 US20040005309A1 (en) | 2002-05-29 | 2002-10-16 | Targeted therapeutic proteins |
| US44573403P | 2003-02-06 | 2003-02-06 | |
| US445734P | 2003-02-06 | ||
| PCT/US2003/017211 WO2003102583A1 (fr) | 2002-05-29 | 2003-05-29 | Proteines therapeutiques ciblees |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1514106A1 EP1514106A1 (fr) | 2005-03-16 |
| EP1514106A4 true EP1514106A4 (fr) | 2007-05-09 |
Family
ID=29716364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03736779A Withdrawn EP1514106A4 (fr) | 2002-05-29 | 2003-05-29 | Proteines therapeutiques ciblees |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1514106A4 (fr) |
| AU (1) | AU2003237314B2 (fr) |
| CA (1) | CA2487815A1 (fr) |
| WO (1) | WO2003102583A1 (fr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7396811B2 (en) | 2001-04-30 | 2008-07-08 | Zystor Therapeutics, Inc. | Subcellular targeting of therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| AU2002347910A1 (en) * | 2001-10-16 | 2003-04-28 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| MXPA05007322A (es) | 2003-01-06 | 2006-02-17 | Angiochem Inc | Aprotinina y analogos como portadores a traves de la barrera sangre-cerebro. |
| CA2553955C (fr) * | 2004-02-10 | 2012-08-28 | Zystor Therapeutics, Inc. | Alpha-glucosidase acide et fragments de celle-ci |
| EP1818395A1 (fr) | 2006-02-08 | 2007-08-15 | Diatos | Compositions et méthodes pour le traitement de maladies lysosomales |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| EP2182980A4 (fr) | 2007-07-27 | 2012-04-18 | Armagen Technologies Inc | Procédés et compositions destinés à augmenter une activité a-iduronidase dans le snc |
| EP3272773B8 (fr) | 2008-05-07 | 2020-11-18 | BioMarin Pharmaceutical Inc. | Peptides de ciblage lysosomal et leurs utilisations |
| BRPI0920209A2 (pt) | 2008-10-15 | 2015-12-22 | Angiochem Inc | conjugados de agonistas de glp-1 e usos dos mesmos |
| WO2010063122A1 (fr) | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Conjugués de neurotensine ou d'analogues de neurotensine et leurs applications |
| EP2373789A4 (fr) | 2008-12-17 | 2012-08-29 | Angiochem Inc | Inhibiteurs de la métalloprotéine matricielle de type 1 membranaire et leurs utilisations |
| RU2011146654A (ru) | 2009-04-20 | 2013-05-27 | Ангиокем Инк. | Способы лечения рака яичников с применением конъюгированного средства |
| ES2569514T3 (es) | 2009-06-17 | 2016-05-11 | Biomarin Pharmaceutical Inc. | Formulaciones para enzimas lisosómicas |
| CN102596993A (zh) | 2009-07-02 | 2012-07-18 | 安吉奥开米公司 | 多聚体肽结合物以及其应用 |
| BR112012033197A2 (pt) | 2010-06-25 | 2017-06-06 | Shire Human Genetic Therapies | métodos e composições para liberação de cns de n-sulfatase de heparano. |
| KR20130043165A (ko) | 2010-06-25 | 2013-04-29 | 샤이어 휴먼 지네틱 테라피즈 인크. | 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들 |
| PL2585104T3 (pl) | 2010-06-25 | 2020-01-31 | Shire Human Genetic Therapies, Inc. | Sposoby i kompozycje do dostarczania arylosulfatazy a do oun |
| AU2011270672B2 (en) | 2010-06-25 | 2017-01-12 | Shire Human Genetic Therapies, Inc. | Treatment of Sanfilippo Syndrome type B |
| KR102211960B1 (ko) | 2010-06-25 | 2021-02-05 | 샤이어 휴먼 지네틱 테라피즈 인크. | 치료제들의 cns 전달 |
| MX354776B (es) | 2010-06-25 | 2018-03-20 | Shire Human Genetic Therapies | Enzimas de reemplazo lisosomal para usarse en el tratamiento de enfermedades de almacenamiento lisosomal. |
| CN104136606A (zh) * | 2011-12-01 | 2014-11-05 | 安吉奥开米公司 | 靶向的艾杜糖-2-硫酸酯酶化合物 |
| WO2013078564A2 (fr) * | 2011-12-01 | 2013-06-06 | Angiochem Inc. | Composés d'enzyme lysosomale vectorisée |
| EP2793922B1 (fr) | 2011-12-23 | 2019-10-30 | Shire Human Genetic Therapies, Inc. | Formulations stables pour l'administration au système nerveux central d'arylsulfatase a |
| AU2013273894A1 (en) * | 2012-06-15 | 2015-02-05 | Angiochem Inc. | Targeted iduronidase compounds |
| ES2729997T3 (es) | 2012-11-27 | 2019-11-07 | Biomarin Pharm Inc | Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas |
| WO2014082184A1 (fr) * | 2012-11-30 | 2014-06-05 | Angiochem Inc. | Composés d'iduronate-2-sulfatase ciblés |
| PL2991683T3 (pl) * | 2013-05-02 | 2020-03-31 | Glykos Finland Oy | Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem |
| WO2014194428A1 (fr) * | 2013-06-06 | 2014-12-11 | Angiochem Inc. | Composés d'héparane sulfatase ciblés |
| EP3682904A1 (fr) | 2014-06-30 | 2020-07-22 | Glykos Finland Oy | Dérivé de saccharide d'une charge utile toxique et conjugués d'anticorps de celui-ci |
| US10556015B2 (en) | 2014-10-24 | 2020-02-11 | Criteo S.A. | Lysosomal targeting of enzymes, and uses thereof |
| JP6823055B2 (ja) | 2015-06-15 | 2021-01-27 | アンジオケム インコーポレーテッド | 軟髄膜癌腫症の治療方法 |
| CA3015358A1 (fr) | 2016-02-24 | 2017-08-31 | Biomarin Pharmaceutical Inc. | Proteines de fusion d'enzymes lysosomales therapeutiques ciblees, formulations associees et leurs utilisations |
| JP7458404B2 (ja) | 2018-12-20 | 2024-03-29 | アーマジェン・インコーポレイテッド | イズロン酸－２－スルファターゼ免疫グロブリン融合タンパク質の精製 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002087510A2 (fr) * | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Ciblage intracellulaire de proteines therapeutiques |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002347910A1 (en) * | 2001-10-16 | 2003-04-28 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
-
2003
- 2003-05-29 AU AU2003237314A patent/AU2003237314B2/en not_active Ceased
- 2003-05-29 EP EP03736779A patent/EP1514106A4/fr not_active Withdrawn
- 2003-05-29 CA CA002487815A patent/CA2487815A1/fr not_active Abandoned
- 2003-05-29 WO PCT/US2003/017211 patent/WO2003102583A1/fr active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002087510A2 (fr) * | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Ciblage intracellulaire de proteines therapeutiques |
Non-Patent Citations (2)
| Title |
|---|
| NOLAN C M ET AL: "BINDING OF INSULIN-LIKE GROWTH FACTOR II (IGF-II) BY HUMAN CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR/IGF-II RECEPTOR EXPRESSED IN RECEPTOR-DEFICIENT MOUSE L CELLS", CELL REGULATION, BETHESDA,MD, US, vol. 1, no. 2, January 1990 (1990-01-01), pages 197 - 213, XP008053772, ISSN: 1044-2030 * |
| See also references of WO03102583A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1514106A1 (fr) | 2005-03-16 |
| WO2003102583A1 (fr) | 2003-12-11 |
| AU2003237314A1 (en) | 2003-12-19 |
| AU2003237314B2 (en) | 2010-03-04 |
| CA2487815A1 (fr) | 2003-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1514106A4 (fr) | Proteines therapeutiques ciblees | |
| GB0206876D0 (en) | Therapeutic agents | |
| GB0229931D0 (en) | Therapeutic agents | |
| GB0209991D0 (en) | Therapeutic agents | |
| GB0209997D0 (en) | Therapeutic agents | |
| GB0209995D0 (en) | Therapeutic agents | |
| GB0210127D0 (en) | Therapeutic agents | |
| GB0230087D0 (en) | Therapeutic agents | |
| GB0210124D0 (en) | Therapeutic agents | |
| GB0230088D0 (en) | Therapeutic agents | |
| GB0223349D0 (en) | Therapeutic agents | |
| GB0218876D0 (en) | Therapeutic agents | |
| GB0219660D0 (en) | Therapeutic use | |
| AU2003226899A8 (en) | Human diabetes-mediating proteins | |
| GB0217068D0 (en) | Therapeutic agents | |
| GB0226462D0 (en) | Therapeutic agents | |
| GB0225501D0 (en) | Therapeutic agents | |
| GB0208394D0 (en) | Therapeutic agents | |
| AU2003231937A8 (en) | Therapeutic methods | |
| GB0215224D0 (en) | Protein | |
| GB0213383D0 (en) | Therapeutic conditions | |
| GB0225399D0 (en) | Therapeutic agents | |
| GB0225923D0 (en) | Therapeutic agents | |
| GB0223496D0 (en) | Therapeutic agents | |
| GB0227256D0 (en) | Therapeutic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20041223 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1076863 Country of ref document: HK |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BEVERLEY, STEPHEN, M. Inventor name: SLY, WILLIAM, S. Inventor name: LEBOWITZ, JONATHAN, H. |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20070405 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BIOMARIN PHARMACEUTICAL INC. |
|
| 17Q | First examination report despatched |
Effective date: 20121031 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20130312 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1076863 Country of ref document: HK |